Introduction

Schizophrenia is a chronic psychotic disorder, often subside, with wide variety of clinical manifestations which is caused by a disruption in certain brain structures. The symptom of schizophrenia in the form of hallucinations, delusions, emotional disturbances, and withdrawal from social environment involves a biological mechanism, which can be seen from neuroimaging and neurological examination [1], [2].

The studies using neuroimaging examinations showed that the change of brain volume in the cortex and subcortex regions of individuals with schizophrenia was also related to changes in neurological soft sign (NSS) which is linked with deficits in the functions of sensory integration, motor coordination, and complex motor movements. NSS can be found in various levels of schizophrenia and is very prominent when compared to healthy populations. Within the neurophysiological scope, there is a significant association of chronicity of the disease with a high NSS score [3], [4]. In our previous NSS study at Makassar, we found that NSS scores were higher in patients with chronic schizophrenia compared to acute patients. Moreover, in 2018 we assessed the relation of NSS scores and the Positive and Negative Syndrome Scale (PANSS) between schizophrenic patients compared to normal controls [5], [6]. Our findings showed that there were solid differences in the NSS scores between patients and controls. Other findings in this research also illustrated the relation between high PANSS score with high NSS scores, especially when looking into cognitive and negative aspects. The research by Herold et al. demonstrated that NSS reflects a rather wide range of cognitive impairments in schizophrenia which is not accounted for by age, education, or severity of global cognitive deficits [7].

Risperidone and haloperidol are antipsychotics commonly used to treat schizophrenic patients in Indonesia. The long-term administration of these two antipsychotics can affect the neurobiology of patients. Previous research by Liebermann et al. comparing risperidone and haloperidol showed that atypical antipsychotic drugs may have neuroprotective effects resulting in an increase in an individual’s cognition functions [8]. This is also supported by the study of He et al. which found signs of neurogenesis
from progenitor cells and an increase of Brain-derived Neurotropic Factor levels in experimental animals who were receiving atypical antipsychotic drugs
[9]. In a study conducted by Van Haren et al., using magnetic resonance imaging, they examined vertex in each individual and found that first-generation antipsychotics like haloperidol resulted in a decrease in cortical mass of schizophrenic patients while the second-generation antipsychotic drug such as risperidone showed a reduction in the decrease of cortical mass in human. The study shows that long-term use of antipsychotic can affect the morphology of human brain which hypothesized may be able to affect brain function [10], [11].

The relations between antipsychotics and NSS itself previously investigated in studies of risperidone and NSS scores showed that patients with high NSS scores indicated slower improvement compared to individuals with low NSS scores [12].

Therefore, we decided to investigate the change observed for NSS scores in schizophrenic patients who were receiving risperidone and haloperidol as antipsychotic therapy.

Methods

Sampling and recruitment

A total of 30 individuals were collected consecutively for each group. The inclusion criteria of this study were patients diagnosed with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorder 5th edition (DSM V), the patients received haloperidol or risperidone at therapeutic doses, PANSS scores below 95, exclusions criteria are no history of substance abuse and no apparent neurological defect.

Design

This Prospective Cohort design study was conducted at Wahidin Sudirohusodo Hospital, Makassar, Indonesia and its networks from January to March 2019. The population of this study was patients diagnosed with schizophrenia (295.90) using DSM V who fulfilled the inclusion criteria of the study.

Data collection

The researcher recorded the identity of each sample, including name, gender, age, education, and history of past illness. Each sample tested in Heidelberg Scales and Mini-mental State Examination at initial week, 4th week, and 8th week of the study.

The Wilcoxon Signed rank is used to assess the relationships of 2 groups of data that are not normally distributed and are paired. This study was used to analyze differences in the total NSS scores according to the Heidelberg scale at week 0, week 4, and week 8 of the study. Researchers also used this test to analyze each Heidelberg scale variable at week 0, week 4, and week 8 of the study. The following results were found In the Haloperidol group, there were no significant changes in NSS scores, both at week 4 and at week 8 (all with p > 0.05). In the risperidone group, there was a significant

Statistical analysis

Statistical analysis was performed using SPSS 20; the result will be presented in the form of data tabulation.

Results

In this research, we calculated of total 60 patients (30 in each group) which comprised more male (63.3%) subject compared to female (36.7%).

The age group showed that majority of the patient was in 30–40 years (55%) followed by 40–50 years (30%) and 20–30 years (15%), respectively. We found that in our study, there are more married subjects (56.67%) than unmarried one (43.33%). The employment group shows us there was more unemployed (68.3%) schizophrenic patient compared to the working one (31.7%).

In our study group, we found that chronic patients (45% and 40%) are more dominant compared with acute one (15%). The study also shows that majority of the patient are treated more than 4 weeks (81.6%) (Table 1).

Table 1: Clinical characteristic of patient in relation with NSS using Kruskal Wallis test for significance

| Variable       | Haloperidol n= 30 | Risperidone n= 30 | Significance (p) |
|----------------|-------------------|-------------------|-----------------|
| Gender         |                   |                   |                 |
| Male           | 20                | 18                | 0.479           |
| Female         | 10                | 12                |                 |
| Age            |                   |                   |                 |
| 20–30 year     | 5                 | 4                 | 0.892           |
| 30–40 year     | 17                | 16                |                 |
| 40–50 year     | 8                 | 10                | 0.123           |
| Marriage       |                   |                   |                 |
| Married        | 18                | 16                | 0.111           |
| Not married    | 12                | 14                |                 |
| Employment     |                   |                   |                 |
| Employed       | 10                | 9                 |                 |
| Unemployed     | 20                | 21                |                 |
| Education      |                   |                   |                 |
| Elementary     | 12                | 5                 | 0.06            |
| Junior high    | 12                | 15                |                 |
| Senior high    | 5                 | 8                 |                 |
| Bachelor       | 1                 | 2                 |                 |
| Onset          |                   |                   |                 |
| <1 year        | 4                 | 5                 | 0.031           |
| 1–5 year       | 13                | 14                |                 |
| >5 year        | 13                | 11                |                 |
| Inward treatment |               |                   |                 |
| <4 weeks       | 7                 | 4                 | 0.045           |
| 4 weeks        | 23                | 26                |                 |

p < 0.05 = significant.

https://oamjms.eu/index.php/mjms/index
decrease in NSS scores, both at week 4 (p < 0.05) and at 8 weeks (p < 0.001). Likewise, between the 4th week and 8th week, there was a significant decrease from 19.8 to 16.8 (p < 0.001). The above results show that risperidone is better than haloperidol in reducing NSS scores (Table 2).

Mann–Whitney is used to compare variables from two data groups that are not normally distributed and are not paired. In this study it is used to analyze the difference in the total NSS score according to the Heidelberg scale between the haloperidol and risperidone groups and to analyze each Heidelberg scale variable in the haloperidol and risperidone groups. Initial measurement showed no significant differences in NSS scores between the two groups, which were around 20.6–20.9 (p > 0.05). Measurement at 4th week still showed no significant difference in NSS scores between the two groups, which was around 19.8–21.6 (p > 0.05). Measurement at 8th week showed NSS scores in the risperidone group (16.8) significantly lower than in the haloperidol group (20.4) (p < 0.01) (Table 3).

Initial measurement using Wilcoxon Signed Rank shows that motor sequencing scores were significantly higher in the risperidone group (5.10) than in the haloperidol group (20.4) (p < 0.01) (Table 3). Initial and following measurement shows that spatial ability scores did not differ significantly between the two groups (each with p > 0.05). Initial motor sequencing scores were significantly lower in the haloperidol group (5.57) than in the risperidone group (1.70) (p < 0.01). Fourth week Motor Sequencing Score, spatial ability and sensory integration did not differ significantly between the two groups (each with p > 0.05). Fourth-week measurement, the motor coordination score was significantly lower in the risperidone group (5.57) than the haloperidol group (7.10) (p < 0.01). Fourth week the Hard Sign Score was significantly lower in the risperidone group (1.70) than the haloperidol group (2.30) (p < 0.05) (Tables 4-6).

Initial measurement using Wilcoxon Signed Rank shows that motor sequencing scores were significantly higher in the risperidone group (5.10) than in the haloperidol group (3.83) (p < 0.05). Initial and following measurement shows that spatial ability scores did not differ significantly between the two groups (each with p > 0.05). Initial measurement shows that Motor Coordination did not differ significantly between the two groups (each with p > 0.05). Initial and following measurement shows Sensory Integration did not differ significantly between the two groups (each with p > 0.05). Initial measurement shows Hard Sign Score was significantly lower in the risperidone group (1.07) than in the haloperidol group (2.67) (p < 0.001) (Tables 4-6).

At the 4th-week Motor Sequencing Score, spatial ability and sensory integration did not differ significantly between the two groups (each with p > 0.05). Fourth-week measurement, the motor coordination score was significantly lower in the risperidone group (5.57) than the haloperidol group (7.10) (p < 0.01). Fourth week the Hard Sign Score was significantly lower in the risperidone group (1.70) than the haloperidol group (2.30) (p < 0.05) (Tables 4-6).

Discussion

This was the first study in Indonesia which revealed that risperidone is superior in improving the magnitude of NSS in schizophrenia patient compared to haloperidol which assumed that risperidone as atypical antipsychotic is far better in improving the cognitive aspect of schizophrenic patient and is highly recommended as a viable choice in long term treatment in Indonesian schizophrenic patient.
In our clinical characteristic, we found that our patients mainly comprised patients with from elementary and high school level education (28% and 45% of the total sample, respectively). Our results were in line with data obtained by Yang et al., also showing that some individuals with higher education had better initial NSS scores than lower education individuals even though statically not significant [13]. This suggested that NSS ability in measuring one’s cognitive function is not related with the educational background of individuals which is also in line with the study from Herold et al. which explains the functions of cognition and education in schizophrenic patients and their relationship with NSS [5].

We found that chronic schizophrenia patients have significantly higher NSS scores than acute patients which proved that chronic schizophrenia patient suffers from more severe neurobiological changes compared to acute schizophrenia patient. This result was the same as shown in a previous study which is conducted by Santosa et al. [5]. In addition, in some acute subjects with dominant-negative symptoms, higher NSS scores were obtained compared to acute individuals with pre-dominant positive symptom. This result showed that patients with negative symptoms had worse cognitive function compared to patients with positive symptoms. These findings revealed a link to possible neurobiological impairment, especially in the prefrontal cortex area and showed a relationship between the cognitive function, negative symptoms, chronicity of disease, and NSS in schizophrenia patient [14].

The length of stay in our subjects illustrates that patients who have been exposed and reintegrated in social life provide better improvement in NSS score compared to hospitalized subjects [15], [16]. This is in line with Kaplan’s theory which emphasizes the importance of social function as one of the pillars in the treatment of patients with schizophrenia [2], [16].

We had been able to show that risperidone as atypical antipsychotic to improving NSS scores is superior to haloperidol. Moreover, a significant change in NSS function, as a reflection of a soft neurological sign that gives a general picture of brain integration function can be seen in 2 months after atypical antipsychotic drug administration. This explained why the majority of the patient showed detachment from symptom at 6 weeks treatment and more. This finding is consistent with some of the very earliest ideas that antipsychotics produced a state of “indifference” and is also consistent with the more recent, neurobiologically informed notions that antipsychotics work by dampening the salience of psychotic symptoms [17].

We found that at the 4 weeks observation, there was an increase in NSS scores of patients who received haloperidol because of the development of extrapyramidal syndrome (EPS). This explained that EPS symptoms can appear at the beginning of therapy in schizophrenic patients and will affect NSS signs [18]. On the other hand, this phenomenon can also be a marker for assessing other EPS risks such as akathisia in individuals with acute schizophrenia and can be a consideration in the long-term management of schizophrenic patients.

Based on the comparison of NSS components in 4th and 8th week, we found that risperidone had a superior benefit compared to haloperidol in motor coordination and motor sequencing with risperidone after 8 weeks of administration. This is in accordance with the theory of neurogenesis as suggested in a study which showed neurogenesis in the corticofrontal structures of experimental animals who received risperidone. Improvements in this structure are thought to have a relationship with improvement in motor integration functions of individuals with schizophrenia [19].

Based on the observed changes in NSS scores in the two treatment groups, we could confirm the superiority of atypical drugs (risperidone) compared to typical drugs (haloperidol). This is supported by the theory of Bachman, who suggested the neuroprotective effects of antipsychotics on NSS [20].

The study is limited by the short timeframe and the sample which is not randomized.

**Conclusions**

In summary, atypical antipsychotics are superior in improving NSS scores and cognitive function of schizophrenia patient compared to typical antipsychotic, we also found that NSS may be used to evaluate the improvement of cognitive function in antipsychotic treatment and also as a tool to differentiate chronic or acute schizophrenia. All of these findings give us insight in the course of schizophrenic patient and long-term treatment for the illness.

**Declarations**

**Authors’ contributions**

All the authors were involved in the conception of this study. WT, EL, SS, and STL, to interpretation of the research findings and contributed to the drafting of the manuscript. All authors read and approved the final manuscript.

**Acknowledgments**

We would like to acknowledge and thank the participants who took part in this study.
Ethics approval and consent to participate

Because we only considered professionals’ views and not those of patients, this project is not subjected to Indonesian’s Health Research Law, and thus approval from The Regional Committee for Medical and Health Research Ethics was not applicable. Therefore, the Hasanuddin University Medical Committee was contacted. The research has been permitted and acknowledged by Hasanuddin University Medical Committee. Before each interview, each participant was given written information on the study. Each participant was also informed that his or her participation was voluntary. Before each interview, we emphasized the importance of maintaining confidentiality in relation to patient cases. All participants provided written consent to participate in the study.

Consent for publication

All participants provided written informed consent for publication.

Availability of data and materials

The datasets used and analyzed for this study are available from the corresponding author on reasonable request.

References

1. Khamker N. First episode schizophrenia. S Afr Fam Pract. 2015;57(5):29-33.
2. Kaplan HI, Sadock BJ. Schizophrenia, Synopsis of Psychiatry. 11th ed. New York: Lippincott Williams & Wilkins.
3. Yang Y, Raine A. Prefrontal structural and functional brain imaging findings in antisocial, violent, and psychopathic individuals: A meta-analysis. Psychiatry Res. 2009;174(2):81-8. https://doi.org/10.1016/j.psychresns.2009.03.012 PMid:19833485
4. Bray T, Cvetic. Soft Neurological Signs and Schizophrenia: A Looking Glass into Core Pathology? Zagreb, Croatia: Medicinka Naklada; 2009.
5. Santos D. Hubungan Tanda Neurologi Lunak dan Gejala Negatif pada Pasien Skizofrenia di Rumah Sakit Dadi di Makassar. Indonesia: PDSKJI; 2002.
6. Judhi H. Hubungan Gejala Klinis Skizofrenia dan Neurological Soft Sign (NSS); 2018.
7. Herold CJ, Lässer MM, Seidl UW, Hirjak D, Thomann PA, Schröder J. Neurological soft signs and psychopathology in chronic schizophrenia: A cross-sectional study in three age groups. Front Psychiatry. 2018;9:98. https://doi.org/10.3389/fpsyt.2018.00098 PMid:29632500
8. Lieberman JA, Tollesford GD, Charles C, Zipursky R, Sharma T, Kahn RS, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005;62(4):361-70. https://doi.org/10.1001/archpsyc.62.4.361 PMid:15809403
9. He J, Kong J, Tan QR, Li XM. Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models. Cell Adh Migr. 2009;3(1):129-37. https://doi.org/10.4161/cam.3.1.740 PMid:19372744
10. van Haren NE, Schnack HG, Cahn W, van den Heuvel MP, Lepage C, Collins L, et al. Changes in cortical thickness during the course of illness in schizophrenia. Arch Gen Psychiatry. 2011;68(9):871-80. https://doi.org/10.1001/archgenpsychiatry.2011.88 PMid:21893656
11. Roiz-Santíañez R, Suarez-Pinilla P, Crespo-Facorro B. Brain structural effects of antipsychotic treatment in schizophrenia: A systematic review. Curr Neuropharmacol. 2015;13(4):422-34. https://doi.org/10.2174/1570159x13666150429002536 PMid:26412062
12. Smith RC, Kadewari RP. Neurological soft signs and response to Risperidone in chronic schizophrenia. Biol Psychiatry. 1996;40(10):1056-9. https://doi.org/10.1016/s0006-3223(96)00251-x PMid:8915566
13. Wu Y, Kang R, Yan Y, Gao K, Li Z, Jiang J, et al. Epidemiology of schizophrenia and risk factors of schizophrenia-associated aggression from 2011 to 2015. J Int Med Res. 2018;46(10):4039-49. https://doi.org/10.1177/0300060518786634 PMid:30088782
14. Chan CK, Xu T, Heinrichs RW, Yu Y, Wang Y. Neurological soft signs in schizophrenia: A Meta-analysis. Schizophr Bull. 2010;36(6):1089-104. https://doi.org/10.1093/schbul/sbp011 PMid:19377058
15. Dazzan P, Robin MR. Neurological soft signs in first-episode psychosis: A systematic review. Br J Psychiatry Suppl. 2002;43:s50-7. https://doi.org/10.1192/bjp.181.43.s50 PMid:12271801
16. Çakmak S, Süt H, Öztürk S, Tamam L, Bal U. The effects of occupational therapy and psychosocial interventions on interpersonal functioning and personal and social performance levels of corresponding patients. Noro Psikiyat Ars. 2016;53(3):234-40. https://doi.org/10.5152/npa.2015.10130 PMid:28373800
17. Mizrahi R, Bagby RM, Zipursky RB, Kapur S. How antipsychotics work: The patients’ perspective. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(5):859-64. https://doi.org/10.1016/j.pnpbp.2005.03.001 PMid:15908094
18. Ogbemini A, Chiliza B, Bello T, Asmal L, Esan O, Emsley R, Gureje O. Neurological soft signs, spontaneous and treatment emergent extrapyramidal syndromes in black Africans with first episode schizophrenia. Front Psychiatry. 2018;9:172. https://doi.org/10.3389/fpsyt.2018.00172 PMid:29780333
19. Nasrallah HA. Impaired Neuroplasticity in Schizophrenia and the Neuro-Regenerative Effects of Atypical Antipsychotics. Virginia: LEN; 2019.
20. Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9):842-51. https://doi.org/10.1056/nejmoa1005987 PMid:21366475